# Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

> **NCT03302728** · PHASE1 · COMPLETED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 6 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Lenalidomide 15mg
- **DRUG:** Brentuximab Vedotin 1.8 mg/Kg

## Key facts

- **NCT ID:** NCT03302728
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-30
- **Primary completion:** 2021-08-02
- **Final completion:** 2021-08-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03302728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03302728, "Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03302728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*